Brief: Genentech's Enspryng Cuts Relapse Risk 68%, Shows Potential as First MOGAD Treatment
21/04/2026 18:30
April 21 (Reuters) - Genentech: GENENTECH’S ENSPRYNG (SATRALIZUMAB) REDUCES RISK OF RELAPSES BY 68% DEMONSTRATING POTENTIAL TO BECOME FIRST TREATMENT FOR MOGAD GENENTECH: PHASE III METEOROID STUDY MET ITS PRIMARY ENDPOINT IN PATIENTS WITH MOGAD Source text: ID:nBw8Msqsha Further company coverage: ROPC.S ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Roche Holding AG
See all newsTable: Swiss trade surplus at CHF 6.11 bln in May
Brief: Roche - FDA Accepts Supplemental Biologics License Application For Lunsumio And Polivy Combination
Swiss stocks - Factors to watch on June 18
FDA approves first generic version of Roche's flu drug
Brief: FDA Approves First Single-Dose Generic Treatment For Influenza